N-{3-(tert-butyl)-1-[4-(methylsulfonyl)phenyl]pyrazol-5-yl}{[4-(4-pyridylmethyl)phenyl]amino}carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-{3-(tert-butyl)-1-[4-(methylsulfonyl)phenyl]pyrazol-5-yl}{[4-(4-pyridylmethyl)phenyl]amino}carboxamide
• 英文别名: N-(1-(4-methanesulfonylphenyl)-3-tert-butyl-5-pyrazolyl)-N'-(4-(4-pyridinylmethyl)phenyl)urea；1-[5-Tert-butyl-2-(4-methylsulfonylphenyl)pyrazol-3-yl]-3-[4-(pyridin-4-ylmethyl)phenyl]urea
• 化学式: C₂₇H₂₉N₅O₃S
• 分子量: 503.625
• InChiKey: UFYLFJPNTBRHEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  114
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY
  申请人：Bayer Healthcare LLC

  公开号：US20160015697A1

  公开（公告）日：2016-01-21

  This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

  这项发明涉及使用芳基脲类化合物治疗由异常血管生成或高渗透性过程特征的VEGF诱导信号转导通路介导的疾病的方法。
• Aryl Ureas With Angiogenisis Inhibiting Activity
  申请人：Dumas Jacques

  公开号：US20080227828A1

  公开（公告）日：2008-09-18

  This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

  本发明涉及使用芳基脲类化合物治疗由VEGF诱导的信号转导通路介导的异常血管生成或高渗透过程引起的疾病的方法。
• ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY
  申请人：DUMAS Jacques

  公开号：US20120289552A1

  公开（公告）日：2012-11-15

  This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

  本发明涉及使用芳基脲类化合物治疗由VEGF诱导的信号转导通路介导的以异常血管生成或高渗透过程为特征的疾病的方法。
• Aryl ureas with angiogenesis inhibiting activity
  申请人：Bayer Healthcare LLC

  公开号：EP2324825A1

  公开（公告）日：2011-05-25

  This invention relates to the use of aryl ureas in the manufacture of a medicament for treating or preventing diseases characterized by abnormal angiogenesis or hyperpermeability processes which are mediated by the VEGF induced signal transduction pathway.

  本发明涉及使用芳基脲类制造一种药物，用于治疗或预防以血管内皮生长因子诱导的信号转导通路介导的异常血管生成或高渗透性过程为特征的疾病。
• Aryl ureas with angiogenisis inhibiting activity
  申请人：Bayer Healthcare LLC

  公开号：US10653684B2

  公开（公告）日：2020-05-19

  This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

  本发明涉及使用芳基脲类治疗由血管内皮生长因子诱导的信号转导通路介导的疾病的方法，这些疾病的特征是血管异常生成或高渗透性过程。